- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01988493
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
August 22, 2022 updated by: Merck KGaA, Darmstadt, Germany
A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function
This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects with MET+, Barcelona Clinic Liver Cancer (BCLC) Stage C, systemic treatment naive advanced hepatocellular carcinoma (HCC) and Child-Pugh class A liver function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
117
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100050
- Beijing Friendship Hospital, Capital Medical University
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Peking University Cancer Hospital
-
Beijing, Beijing, China, 100071
- 307 Hosptial of PLA
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University, Cancer Center
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- Harbin Medical University Cancer Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410013
- The Third Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210002
- Nanjing Bayi Hospital
-
Nanjing, Jiangsu, China, 210029
- Nanjing First Hospital Affiliated to Nanjing Medical University
-
-
Jilin
-
Changchun, Jilin, China, 130012
- Jilin Cancer Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Zhongshan Hospital Fudan University
-
Shanghai, Shanghai, China, 200032
- Shanghai Cancer Hospital, Fudan University
-
-
Zhejiang
-
Tianjin, Zhejiang, China, 300060
- Cancer Hospital, Tianjin Medical University
-
Zhejiang, Zhejiang, China, 310016
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
-
-
-
-
-
Busan, Korea, Republic of, 602-739
- Pusan National University Hospital
-
Busan, Korea, Republic of, 602-715
- Dong-A University Hospital
-
Daegu, Korea, Republic of, 700-721
- Kyungpook National University Hospital
-
Daegu, Korea, Republic of, 41931
- Keimyung University Dongsan Hospital
-
Goyang-si, Korea, Republic of, 10408
- National Cancer Center
-
Seongnam-si, Korea, Republic of, 13620
- Seoul National University Bundang Hospital
-
Seongnam-si,, Korea, Republic of, 13496
- CHA Bundang Medical Center, CHA University
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center
-
Seoul, Korea, Republic of, 02447
- Kyung Hee University Hospital
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
Seoul, Korea, Republic of, 06591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
Seoul, Korea, Republic of, 06273
- Gangnam Severance Hospital, Yonsei University Health System
-
Seoul, Korea, Republic of, 08308
- Korea University Guro Hospital
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 03722
- Severance Hospital, Yonsei University
-
Seoul, Korea, Republic of, 110744
- Seoul National University Hospital
-
Suwon-si, Korea, Republic of, 443-380
- Ajou University Hospital
-
Yangsan, Korea, Republic of, 626-770
- Pusan National University Yangsan Hospital
-
-
-
-
-
Changhua, Taiwan, 50004
- Changhua Christian Hospital
-
Kaohsiung, Taiwan, 807
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Kaohsiung, Taiwan, 83301
- Kaohsiung Chang Gung Memorial Hospital
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Tainan, Taiwan, 736
- Chi Mei Medical Center, Liou Ying
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital
-
Taoyuan, Taiwan, 333
- Chang Gung Memorial Hospital, Linkou
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically confirmed HCC
- Participants were either intermediate HCC of BCLC Stage B, who were not eligible for surgical and/or local-regional therapies or who had progressive disease (PD) after surgical and/or local-regional therapies (note: the local-regional therapy must not contain sorafenib), or advanced HCC of BCLC Stage C
- Participants who had disease progression on or were intolerant to the prior standard treatment for advanced HCC (phase Ib Korean subjects only)
- A tumor biopsy was required for determining MET status
- MET+ status (Phase 2 only), as determined by the central laboratory (Phase 1b retrospectively, Phase 2 for participant selection) were defined in the protocol
- Child-Pugh class A with no encephalopathy according to the screening assessment
- Asian male or female, 18 years of age or older
- Measurable disease in accordance with RECIST v1.1 (Phase 2 only)
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2
- Eligible for treatment with sorafenib, was assessed by investigators according to the Package Insert and clinical judgment (Phase 2 only)
- Signed and dated informed consent indicating that the participants had been informed of all the pertinent aspects of the trial prior to enrollment
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures
- Life expectancy was judged by the investigator of at least 3 months
Exclusion Criteria:
- Prior systemic anticancer treatment for advanced HCC, included targeted therapy (for example, sorafenib), chemotherapy, or any other investigational agent (Phase 2 only)
- Prior treatment with any agent targeting the hepatocyte growth factor (HGF)/c-Met pathway
- Prior local-regional therapy within 4 weeks prior to Day 1 of trial treatment
- Prior history of liver transplant
- Laboratory index at baseline were defined in the protocol
- Past or current history of neoplasm other than HCC, except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at least 5 years
- Known central nervous system (CNS) or brain metastasis that is either symptomatic or untreated
- Medical history of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested products
- Clinically significant gastrointestinal bleeding within 4 weeks before trial entry
- Peripheral neuropathy Grade greater than or equal to 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0)
- Impaired cardiac function was defined in the protocol
- Hypertension uncontrolled by standard therapies
- Participants with a family history of long QT syndrome or who take any agent that is known to prolong QT/QTc interval
- Known human immunodeficiency virus (HIV) infection
- Particpants who had acute pancreatitis and/or chronic pancreatitis, with elevated lipase and/or amylase, clinical symptoms, and/or imaging studies that are indicative of the diagnosis (Mainland Chinese participants only)
- Known or suspected drug hypersensitivity to any ingredients of sorafenib (Phase 2 only) and MSC2156119J
- Female participants who were pregnant or lactating, or males and females of reproductive potential not willing or not able to employ a highly effective method of birth control/contraception to prevent pregnancy from 2 weeks before receiving study drug until 3 months after receiving the last dose of study drug
- Concurrent treatment with a non-permitted drug
- Substance abuse, other acute or chronic medical or psychiatric condition, or laboratory abnormalities that may increase the risk associated with trial participation in the opinion of the investigator
- Participation in another clinical trial within the past 28 days
- Previous anticancer treatment-related toxicities not recovered to baseline or Grade 0-1 (except alopecia and peripheral neuropathy)
- Participants with any concurrent medical condition or disease that will potentially compromise the conduct of the study at the discretion of the investigators
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1b: Tepotinib 300 mg
Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Experimental: Phase 1b: Tepotinib 500 mg
Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Experimental: Phase 1b: Tepotinib 1000 mg
Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
|
Experimental: Phase 2: Tepotinib
Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Experimental: Phase 2 Sorafenib
Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity
Time Frame: Day 1 to Day 21 of Cycle 1 (each cycle is 21 days)
|
Dose limiting toxicity (DLT) was defined as toxicities at any dose level and judged to be related to the study treatment by investigator and/or the sponsor.
DLTs included Grade 4 neutropenia for more than 7 days; Grade greater than or equal to (>=) 3 febrile neutropenia for more than 1 day; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with non-traumatic bleeding; Grade >= 3 uncontrolled nausea/vomiting and/or diarrhea despite adequate and optimal treatment and Grade >= 3 any non-hematological adverse event (AE), except the aforementioned gastrointestinal events and alopecia.
Number of participants who experienced DLT during phase 1b were reported.
|
Day 1 to Day 21 of Cycle 1 (each cycle is 21 days)
|
Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
Time Frame: Baseline up to Day 30 after the last dose of study treatment, assessed up to 94 weeks
|
An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.
Treatment-emergent are events between first dose of study drug and assessed up to 94 weeks.
TEAEs include both Serious TEAEs and non-serious TEAEs.
|
Baseline up to Day 30 after the last dose of study treatment, assessed up to 94 weeks
|
Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC)
Time Frame: From randomization to date of the observation of radiological progressive disease, assessed up to maximum 3.8 years
|
TTP was defined as the time in months from randomization to date of the observation of radiological progressive disease (PD) (based on Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) assessed by an IRC.
PD is defined as at least 20 percent (%) increase in sum of diameters of target lesions, taking as reference as smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions.
The sum must demonstrate an absolute increase of at least 5 millimeter (mm).
|
From randomization to date of the observation of radiological progressive disease, assessed up to maximum 3.8 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 2: Progression Free Survival (PFS) Time Based on Tumor Assessment by the Independent Review Committee (IRC)
Time Frame: Up to 2.8 years
|
Progression-free survival (PFS) time was defined as the time in months from randomization to either first observation of disease progression (based on RECIST v1.1) or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment.
PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions.
The sum must also demonstrate an absolute increase of at least 5 millimeter(mm).
PFS was measured using Kaplan-Meier (KM) estimates.
|
Up to 2.8 years
|
Phase 2: Overall Survival (OS)
Time Frame: Time from randomization to the date of death or up to 6.9 years
|
Overall survival time was measured as time in months between the date of randomization and the date of death.
|
Time from randomization to the date of death or up to 6.9 years
|
Phase 2: Time to Progression (TTP) Based on Tumor Assessment by Investigator
Time Frame: From randomization to date of the observation of radiological progressive disease, assessed up to maximum 2.8 years
|
TTP was defined as the time in months from randomization to date of the observation of radiological PD (based on RECIST v1.1) assessed by the investigator.
PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions.
The sum must also demonstrate an absolute increase of at least 5 mm.
|
From randomization to date of the observation of radiological progressive disease, assessed up to maximum 2.8 years
|
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-infinity) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration is at or above the lower limit of quantification (LLLQ).
AUC(0-t) was calculated according to the mixed log-linear trapezoidal rule.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Area Under the Plasma Concentration-Time Curve Within 1 Dosing Interval (AUC 0-tau) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
AUC (0-tau) is the area under the plasma concentration time curve within 1 dosing interval.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Maximum Observed Plasma Concentration (Cmax) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Cmax is the maximum observed plasma concentration obtained directly from the concentration versus time curve.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Minimum Observed Plasma Concentration (Cmin) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 15 of Cycle 1 (each Cycle is 21 days)
|
Cmin is minimum observed plasma concentration obtained directly from the concentration versus time curve.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Average Observed Plasma Concentration (Cav) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 15 of Cycle 1 (each Cycle is 21 days)
|
Cavg is the average plasma concentration within 1 dosing interval obtained directly from the concentration versus time curve.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Time to Reach Maximum Plasma Concentration (Tmax) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Tmax is time to reach maximum observed plasma concentration obtained directly from the concentration versus time curve.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Apparent Volume of Distribution During the Terminal Phase (Vz/f) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
The Vz/f was defined as the theoretical volume in which the total amount of required to uniformly distribute to produce the desired plasma concentration.
Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed.
The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant Lambda(z).
Vz/f=Dose/AUC(0-inf)* Lambda(z).
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Apparent Total Body Clearance From Plasma (CL/f) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
The CL/f is a measure of the rate at which it was metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose was influenced by the fraction of the dose absorbed.
The CL/F from plasma was calculated using the formula: Dose divided by area under the concentration time curve from time zero to infinity (AUC0-inf).
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Apparent Volume of Distribution During the Steady State (Vss/f) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Vss/f after oral dose was influenced by the fraction absorbed.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Apparent Terminal Elimination Rate Constant Lambda(z) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Lambda(z) was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 1b: Apparent Terminal Half-life (t1/2) of Tepotinib
Time Frame: Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.
|
Predose and at 0.25, 0.5, 1, 2, 4, 8, 10, and 24 hours postdose; Day 1 and Day 15 of Cycle 1 (each Cycle is 21 days)
|
Phase 2: Time-to-Symptomatic Progression (TTSP)
Time Frame: Up to 6.9 years
|
Time-to-symptomatic progression was defined as time (in months) from first study drug administration to the date of deterioration of symptoms assessed by Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8) (defined as at least a 4-point increase, i.e., higher score, compared with baseline value), or deterioration to Eastern Cooperative Oncology Group (ECOG) performance score 4, or death.
FHSI-8 assesses hepatobiliary cancer symptoms with total score ranges from 0 to 32 (0 = the best quality of life; 32 = the worst quality of life with severe symptoms).
ECOG assess participant's performance status on a scale of 0 to 5, where 0=fully active and 5=dead.
|
Up to 6.9 years
|
Phase 2: Objective Response Rate (ORR) Based on Tumor Assessment by the IRC
Time Frame: Time from randomization until the first occurrence of PD assessed up to 6.9 years
|
The objective response rate (ORR) was defined as the percentage of participants who had achieved complete response (CR) or partial response (PR) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization until the first occurrence of PD.
CR: Complete Response (CR) defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
Partial response (PR) defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
PD defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.
|
Time from randomization until the first occurrence of PD assessed up to 6.9 years
|
Phase 2: Percentage of Participants With Disease Control Based on Tumor Assessment by IRC According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
Time Frame: Time from randomization until the first occurrence of PD assessed up to 6.9 years
|
Disease control was defined as CR, PR, or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization until the first occurrence of PD.
CR defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
PR defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.
Percentage of participants with disease control were reported.
|
Time from randomization until the first occurrence of PD assessed up to 6.9 years
|
Phase 2: Progression-free Survival (PFS) Based on Tumor Assessment by the Investigator
Time Frame: Time from randomization to disease progression or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment, assessed up to 6.9 years
|
Progression-free survival (assessed by the Investigator) time was defined as the time in months from randomization to either first observation of radiologically confirmed progression disease by the investigator or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment.
PD is defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study; and/or unequivocal progression of existing non-target lesions and/or the presence of new lesions.
The sum must also demonstrate an absolute increase of at least 5 mm.
PFS was measured using Kaplan-Meier (KM) estimates.
|
Time from randomization to disease progression or occurrence of death due to any cause within 84 days of either randomization or the last tumor assessment, assessed up to 6.9 years
|
Phase 2: Objective Response Rate (ORR) Based on Tumor Assessment by the Investigator
Time Frame: Time from randomization until the first occurrence of PD assessed up to 6.9 years
|
The objective response rate was defined as the percentage of participants who had achieved CR or PR as the best overall response according to radiological assessments as adjudicated by the investigator from randomization until the first occurrence of PD.
CR defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
PR defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.
|
Time from randomization until the first occurrence of PD assessed up to 6.9 years
|
Phase 2: Percentage of Participants With Disease Control Based on Tumor Assessment by Investigator According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
Time Frame: Approximately up to 6.9 years
|
Disease control was defined as CR, PR, or stable disease (SD) as the best overall response according to radiological assessments as adjudicated by the IRC from randomization until the first occurrence of PD.
CR defined as disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm.
PR defined as at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
PD was defined as an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum of the diameters of target lesions recorded since treatment started.
Percentage of participants with disease control were reported.
|
Approximately up to 6.9 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R. Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations. Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. doi: 10.1007/s00280-022-04441-3. Epub 2022 Jun 30.
- Ryoo BY, Cheng AL, Ren Z, Kim TY, Pan H, Rau KM, Choi HJ, Park JW, Kim JH, Yen CJ, Lim HY, Zhou D, Straub J, Scheele J, Berghoff K, Qin S. Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. Br J Cancer. 2021 Jul;125(2):200-208. doi: 10.1038/s41416-021-01380-3. Epub 2021 May 10.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 6, 2014
Primary Completion (Actual)
February 5, 2018
Study Completion (Actual)
December 3, 2020
Study Registration Dates
First Submitted
November 1, 2013
First Submitted That Met QC Criteria
November 13, 2013
First Posted (Estimate)
November 20, 2013
Study Record Updates
Last Update Posted (Actual)
August 24, 2022
Last Update Submitted That Met QC Criteria
August 22, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Sorafenib
- Tepotinib
Other Study ID Numbers
- 200095-004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Hepatocellular
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
Clinical Trials on Tepotinib 300 mg
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...Completed
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Merck KGaA, Darmstadt, GermanyCompleted
-
Bausch Health Americas, Inc.CompletedRheumatoid ArthritisUnited States
-
Novartis PharmaceuticalsCompletedChronic Plaque PsoriasisUnited States
-
Radboud University Medical CenterUnknownAcute Kidney Injury | Critically Ill ChildrenNetherlands
-
King Abdullah International Medical Research CenterNovartisTerminatedMyeloid Leukemia, ChronicSaudi Arabia
-
CVI PharmaceuticalsUnknown
-
City Clinical Hospital No.52 of Moscow Healthcare...Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry...Active, not recruitingCoronavirus InfectionsRussian Federation
-
Cognition TherapeuticsNational Institute on Aging (NIA)CompletedAlzheimer DiseaseUnited States